AVENIO ctDNA Targeted Kit – Tumor Profiling

Material Number: N/A

Next-generation sequencing (NGS) liquid biopsy tumor profiling assay for identifying genomic aberrations in solid tumors containing 17 genes.

Technical Datasheet: Technical datasheet

Description

The AVENIO ctDNA Targeted Kit is a next-generation sequencing (NGS) liquid biopsy assay that contains 17 genes, including those in U.S. National Comprehensive Cancer Network (NCCN) Guidelines1. The Targeted panel may be used for pan-cancer research applications, but is specially optimized for lung cancer and colorectal cancer (CRC). The AVENIO ctDNA Targeted Kit is an efficient tumor profiling solution.

 

Specifications:

  • Panel size: 81 kb
  • Sample size: 4 ml of plasma
  • ctDNA input 10-50 ng
  • Reactions per kit: 16
  • Turn-around time 5 days from extraction to results

Product Highlights: An accurate detection of all four mutation classes with high sensitivity and specificity 2, 3 with >99% sensitivity for SNVs, indels, CNVs and fusions and >99% positive predictive value (PPV) for all classes of mutations).

The present kit includes the following subkits:
For more information or further assistance, please reach out to our local representative through the contact form.

Table demonstrating the performance of AVENIO ctDNA kits

The AVENIO ctDNA Analysis Kits are a portfolio of three NGS liquid biopsy assays for oncology research. These assays provide an end-to-end tumor profiling and longitudinal tumor burden monitoring solution.

AVENIO_ctDNA_Tumor_Tissue_Targeted_Panel

References:

  1. National Comprehensive Cancer Network. October 15, 2016
  2. Newman AM, Bratman SV, To J, et al. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nature Medicine. 2014;20(5):548–554. doi:10.1038/nm.3519
  3. Data on file.